<SEC-DOCUMENT>0001213900-21-049294.txt : 20210922
<SEC-HEADER>0001213900-21-049294.hdr.sgml : 20210922
<ACCEPTANCE-DATETIME>20210922090146
ACCESSION NUMBER:		0001213900-21-049294
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20210922
FILED AS OF DATE:		20210922
DATE AS OF CHANGE:		20210922

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Inspira Technologies OXY B.H.N. Ltd
		CENTRAL INDEX KEY:			0001837493
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40303
		FILM NUMBER:		211268260

	BUSINESS ADDRESS:	
		STREET 1:		HATIDHAR 2
		STREET 2:		11TH FLOOR
		CITY:			RA'ANANA
		STATE:			L3
		ZIP:			4366504
		BUSINESS PHONE:		972-9-9664488

	MAIL ADDRESS:	
		STREET 1:		HATIDHAR 2
		STREET 2:		11TH FLOOR
		CITY:			RA'ANANA
		STATE:			L3
		ZIP:			4366504
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea147793-6k_inspiratech.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PURSUANT TO RULE 13a-16 OR 15d-16</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For the Month of: September 2021 (Report No.
2) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission File Number: 001-40303</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Inspira Technologies Oxy B.H.N. Ltd.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Translation of registrant&rsquo;s name into
English)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2 Ha-Tidhar St.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Ra&rsquo;anana 4366504, Israel</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Address of principal executive office)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT>&nbsp;Form
20-F&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT>&nbsp;Form 40-F</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>CONTENTS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 22, 2021, Inspira
Technologies Oxy B.H.N. Ltd., or the registrant, issued a press release titled &ldquo;Inspira Technologies&rsquo; &ldquo;Artificial Lung&rdquo;
to Acquire a Digital Edge: The Company Contracted GlobalLogic, a Hitachi Group Company, for Advanced Digital Product Engineering Services,&rdquo;
a copy of which is furnished as Exhibit 99.1 with this report of foreign private issuer on Form 6-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="background-color: white">The first
two and the fifth paragraphs and the section titled &ldquo;Forward-Looking Statements&rdquo; in the press release are&nbsp;incorporated
by reference into the Registrant&rsquo;s Registration Statement on Form S-8 (Registration No.&nbsp;333-259057), filed with the Securities
and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents
or reports subsequently filed or furnished.</FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="background-color: white">
    <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: top; width: 10%"><FONT STYLE="font-size: 10pt"><B>Exhibit&nbsp;No.</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; vertical-align: bottom; width: 89%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="ea147793ex99-1_inspiratech.htm"><FONT STYLE="font-size: 10pt">Press Release issued by Inspira Technologies Oxy B.H.N. Ltd. on September 22, 2021, titled &ldquo;Inspira Technologies&rsquo; &ldquo;Artificial Lung&rdquo; to Acquire a Digital Edge: The Company Contracted GlobalLogic, a Hitachi Group Company, for Advanced Digital Product Engineering Services.&rdquo;</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SIGNATURES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-size: 10pt"><B>Inspira Technologies Oxy B.H.N. Ltd.</B></FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Date: September 22, 2021</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Dagi Ben-Noon</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="width: 31%"><FONT STYLE="font-size: 10pt">Dagi Ben-Noon</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea147793ex99-1_inspiratech.htm
<DESCRIPTION>PRESS RELEASE ISSUED BY INSPIRA TECHNOLOGIES OXY B.H.N. LTD. ON SEPTEMBER 22, 2021, TITLED "INSPIRA TECHNOLOGIES' "ARTIFICIAL LUNG" TO ACQUIRE A DIGITAL EDGE: THE COMPANY CONTRACTED GLOBALLOGIC, A HITACHI GROUP COMPANY, FOR ADVANCED DIGITAL PRODUCT ENGINE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><IMG SRC="ex99-1_001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Inspira
Technologies&rsquo; &ldquo;Artificial Lung&rdquo; to Acquire a Digital Edge:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>The
Company Contracted GlobalLogic, a Hitachi Group Company, for<BR>
 <U><FONT STYLE="background-color: white">Advanced Digital Product Engineering
Services</FONT></U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Ra&rsquo;anana,
Israel / September 22, 2021/ -- Inspira Technologies OXY B.H.N. Ltd (&ldquo;Inspira Technologies&rdquo; or the &ldquo;Company&rdquo;)
<B>(Nasdaq: IINN, IINNW)</B>, a specialty medical device company engaged in the research, development, manufacturing, and marketing of
proprietary respiratory support technologies</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">, <FONT STYLE="background-color: white">&nbsp;announced
today that the the ART&rsquo;s device &ldquo;brain&rdquo; is to acquire an algorithm enhanced digital platform, for which the Company has contracted
GlobalLogic, a Hitachi Group Company (&ldquo;GlobalLogic&rdquo;), a world leader in digital product engineering.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
&ldquo;brain&rdquo; of the ART device is an algorithm-enhanced control platform. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
unique feature of the ART&rsquo;s &ldquo;brain&rdquo; is the algorithm-based &ldquo;hemo-protective patient&rsquo;s flow rate&rdquo;&ndash; an
algorithm that is designed to manage the early rebalancing of the patient&rsquo;s oxygen saturation levels. <FONT STYLE="background-color: white">In
addition, it includes a digital algorithm enhanced platform designed to activate and control proprietary technologies and data collected
from advanced sensors that measure oxygen saturation, blood temperature, haemoglobin, and haematocrit as well as pressure and flow of
blood.&nbsp;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Dagi
Ben-Noon, Inspira&rsquo;s CEO,</B> stated: &ldquo;With concern over the rising morbidity associated with the COVID-19 pandemic, Inspira Technologies
is progressing towards the production phase of the ART device&rsquo;s &ldquo;brain&rdquo;, an algorithm enhanced platform. The ART is
designed to provide oxygenation of blood and removal of carbon dioxide from the blood. With GlobalLogic, we are pleased&nbsp;to integrate
an advanced digital algorithm into our innovative control platform and to provide a more advanced digital experience for the medical
personnel who will use it.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Chet
Kolley, Group Vice President, Health Care and Life Sciences, GlobalLogic, stated: &ldquo;We have all witnessed the wide-reaching impact
of COVID-19 and the stress it has created on healthcare resources. It&rsquo;s very gratifying to see industry leaders stepping forward
to solve these critical problems. We are thrilled to work with Inspira Technologies on this game-changing technology and looking forward
to the potential positive impact it will have on human lives.&rdquo; </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Inspira
Technologies selected GlobalLogic for its vast experience in working with regulated industries such as medical device and pharmaceutical
companies.&nbsp;GlobalLogic works with many of the world&rsquo;s leading&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">medical
technology, healthcare, and life sciences<FONT STYLE="background-color: white">&nbsp;organizations to create world-class digital patient
experiences, get products to market faster, uncover and capture new revenue streams, and transform healthcare through technology and
innovation.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="background-color: white">&nbsp;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="background-color: white">&nbsp;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="background-color: white"></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex99-1_002.jpg" ALT="">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><IMG SRC="ex99-1_001.jpg" ALT="">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Inspira
Technologies OXY B.H.N. Ltd.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><U>&nbsp;</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inspira
Technologies is an innovative medical device company in the respiratory care industry. Inspira is developing the ART device, a cost effective
early extracorporeal respiratory support system with an intent to function as an &ldquo;Artificial Lung&rdquo; for deteriorating respiratory
patients. The ART device designed to utilize a hemo-protective flow approach aimed to rebalance saturation levels while patients are
awake and breathing, potentially minimizing the patient&rsquo;s need for mechanical ventilation. The Company&rsquo;s product has not yet been
tested or used in humans and has not been approved by the U.S. Food and Drug Administration (FDA).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
more information, please visit our corporate website:&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">https://inspira-technologies.com/</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>About
GlobalLogic</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">GlobalLogic
(www.globallogic.com)&nbsp;is a leader in digital product&nbsp;engineering.&nbsp;&nbsp;We&nbsp;help brands across the globe design&nbsp;and
build innovative products, platforms, and digital experiences for the modern world.&nbsp; By integrating&nbsp;experience&nbsp;design,
complex engineering, and&nbsp;data&nbsp;expertise&nbsp;-- we help our clients imagine what&rsquo;s possible and accelerate their transition
into tomorrow&rsquo;s digital businesses.&nbsp; Headquartered in Silicon Valley, GlobalLogic operates design studios and engineering
centers around the world, extending our deep expertise to customers in the healthcare and life sciences, communications,&nbsp;financial
services, automotive,&nbsp;technology, media and entertainment, manufacturing, and semiconductor industries.&nbsp;&nbsp;GlobalLogic&nbsp;is
a Hitachi Group Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward-Looking
Statement Disclaimer</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">This
press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. For example, the Company
is using forward-looking statements when it discusses that its ART has the potential to acquire a digital which is intended to minimize
the need for mechanical ventilation, and that the collaboration with GlobalLogic will have a potential positive impact on human lives.These
forward-looking statements and their implications are based on the current expectations of the management of the Company only and are
subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking
statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking
statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed
information about the risks and uncertainties affecting the Company is contained under the heading &ldquo;Risk Factors&rdquo; in the
Company&rsquo;s Registration Statement on Form F-1 filed with the SEC, which is available on the SEC&rsquo;s website, www.sec.gov.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>For
more details:</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Miri
Segal, Investor Relations, MS-IR LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">+917-607-8654,
msegal@ms-ir.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michal
Efraty, Public Relations &amp; IR</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">+972-54-5648046,
rony@inspirao2.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex99-1_002.jpg" ALT="">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  I ',# 2(  A$! Q$!_\0
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M-P=+1#;QR;"JG82V<'H0!^-6O$5_X_\ B#I3>'$\'/HMK=,@N+RZN P50P/
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*>FT4 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ex99-1_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  I JP# 2(  A$! Q$!_\0
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M_7.X_G'7@M 'MG_#26O_ /0$TW_OJ3_&C_AI+7_^@)IO_?4G^->)T4 >V?\
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M\=* /:O^&DM?_P"@)IO_ 'U)_C1_PTEK_P#T!--_[ZD_QKQ.E((Z@B@#VO\
MX:2U_P#Z FF_]]2?XT?\-):__P! 33?^^I/\:\5 )Z#IUH )Z#/>@#VK_AI+
M7_\ H":;_P!]2?XT?\-):_\ ] 33?^^I/\:\5 )Z#IR:3!QF@#VO_AI+7_\
MH":;_P!]2?XT?\-):_\ ] 33?^^I/\:\4P<9I2".H(SS0![5_P -):__ - 3
M3?\ OJ3_ !H_X:2U_P#Z FF_]]2?XUXJ00<$$'WJ;R)6@:X\MS"K!6D"G:&(
M. 3ZG!_(T >R?\-):_\ ] 33?^^I/\:/^&DM?_Z FF_]]2?XUXNB2/NVJS;1
MN.!T'K4= 'MG_#26O_\ 0$TW_OJ3_&C_ (:2U_\ Z FF_P#?4G^->)U($<QE
MPIV @%L< T >T?\ #26O_P#0$TW_ +ZD_P :/^&DM?\ ^@)IO_?4G^->)T4
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M+F6\U&Y@ME,-_;?*%67<P()QL"$-GS.F<TFB:3ID^D6FDP0WMM<>)HYKAKV
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M ,17TS10!\S?\,W^)_\ H+Z1_P!]2?\ Q%'_  S?XG_Z"^D?]]2?_$5],T4
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M?_H+Z1_WU)_\11_PS?XG_P"@OI'_ 'U)_P#$5],T4 ?,W_#-_B?_ *"^D?\
M?4G_ ,11_P ,W^)_^@OI'_?4G_Q%?3-% 'S-_P ,W^)_^@OI'_?4G_Q%'_#-
M_B?_ *"^D?\ ?4G_ ,17TS10!\S?\,W^)_\ H+Z1_P!]2?\ Q%'_  S?XG_Z
M"^D?]]2?_$5],T4 ?,W_  S?XG_Z"^D?]]2?_$4?\,W^)_\ H+Z1_P!]2?\
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M_P ,W^)_^@OI'_?4G_Q%'_#-_B?_ *"^D?\ ?4G_ ,17TS10!\S?\,W^)_\
MH+Z1_P!]2?\ Q%'_  S?XG_Z"^D?]]2?_$5],T4 ?,W_  S?XG_Z"^D?]]2?
M_$4?\,W^)_\ H+Z1_P!]2?\ Q%?3-% 'S-_PS?XG_P"@OI'_ 'U)_P#$4?\
M#-_B?_H+Z1_WU)_\17TS10!\S?\ #-_B?_H+Z1_WU)_\11_PS?XG_P"@OI'_
I 'U)_P#$5],T4 ?,Z?LY>)E96_M?2."#]Z3_ .(KZ74;4 ]*6B@#_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
